MA27019A1 - Utilisation des derives de la pyrazoline dans la preparation d'un medicament pour la prevention et/ou le traitement des maladies de la proliferation des cellules. - Google Patents
Utilisation des derives de la pyrazoline dans la preparation d'un medicament pour la prevention et/ou le traitement des maladies de la proliferation des cellules.Info
- Publication number
- MA27019A1 MA27019A1 MA27382A MA27382A MA27019A1 MA 27019 A1 MA27019 A1 MA 27019A1 MA 27382 A MA27382 A MA 27382A MA 27382 A MA27382 A MA 27382A MA 27019 A1 MA27019 A1 MA 27019A1
- Authority
- MA
- Morocco
- Prior art keywords
- methyl
- trifluoromethyl
- hydrogen
- fluorine
- aminosulfonyl
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 150000003219 pyrazolines Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- -1 methoxy, trifluoromethoxy, methylsulfonyl Chemical group 0.000 abstract 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 8
- 229910052731 fluorine Inorganic materials 0.000 abstract 7
- 239000011737 fluorine Substances 0.000 abstract 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 5
- 229910052801 chlorine Inorganic materials 0.000 abstract 5
- 239000000460 chlorine Substances 0.000 abstract 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000005599 alkyl carboxylate group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000003857 carboxamides Chemical class 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
UTILISATION DES DERIVES DE LA PYRAZOLINE DANS LA PREPARATION D'UN MEDICAMENT POUR LA PREVENTION ET/OU LE TRAITEMENT DES MALADIES DE LA PROLIFERATION DES CELLULES Dérivés de la pyrazoline (I), dans laquelle R1 est hydrogène, méthyle, fluorométhyle, difluorométhyle, trifluorométhyle, acide carboxylique, carboxylate d'alkyle ayant de 1 à 4 atomes de carbone, carboxamide ou cyano, R2 est hydrogène ou méthyle, R3, R4, R7 et R8, sont indépendamment hydrogène, chlore, fluor, méthyle, trifluorométhyle ou méthoxy, R5 et R6, indépendamment, sont hydrogène, chlore, fluor, méthyle, trifluorométhyle, méthoxy, trifluorométhoxy, méthylsulfonyle, aminosulfonyle ou acétylaminosulfonyle, à la condition que l'un des substituants R5 ou R6 soit un groupe méthylsulfonyle, aminosulfonyle ou acétylaminosulfonyle, et à la condition que lorsque R1 est méthyle, alors R2 est hydrogène ou méthyle, R3 et R8, sont indépendamment hydrogène, chlore, fluor, méthyle ou trifluorométhyle, R4 est hydrogène, fluor, méthyle, trifluorométhyle ou méthoxy, R5 est fluor, 25 trifluorométhyle, trifluorométhoxy, méthylsulfonyle, aminosulfonyle ou acétylaminosulfonyle, R6, est hydrogène, chlore, fluor, méthyle, trifluorométhyle, méthoxy, ; trifluorométhoxy, méthylsulfonyle, aminosulfonyle ou acétylaminosulfonyle, à la condition que l'un des substituants R5 ou R6 soit un groupe méthylsulfonyle, aminosulfonyle ou acétylaminosulfonyle, et R7 représente un atome d'hydrogène, le chlore, le fluor, un groupe méthyle, trifluorométhyle ou méthoxy; utiles pour la prévention ou le traitement des maladies de la prolifération des cellules.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200100818A ES2174757B1 (es) | 2001-04-06 | 2001-04-06 | Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27019A1 true MA27019A1 (fr) | 2004-12-20 |
Family
ID=8497370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27382A MA27019A1 (fr) | 2001-04-06 | 2003-11-05 | Utilisation des derives de la pyrazoline dans la preparation d'un medicament pour la prevention et/ou le traitement des maladies de la proliferation des cellules. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040034082A1 (fr) |
| EP (2) | EP1516621A3 (fr) |
| JP (1) | JP4451599B2 (fr) |
| KR (1) | KR20040025912A (fr) |
| CN (2) | CN1299682C (fr) |
| AT (1) | ATE326966T1 (fr) |
| AU (1) | AU2002246152B2 (fr) |
| BR (1) | BR0208805A (fr) |
| CA (1) | CA2442974C (fr) |
| CY (1) | CY1105523T1 (fr) |
| DE (1) | DE60211681T2 (fr) |
| DK (1) | DK1384477T3 (fr) |
| ES (2) | ES2174757B1 (fr) |
| HU (1) | HUP0400918A3 (fr) |
| IL (1) | IL158269A0 (fr) |
| IS (1) | IS6973A (fr) |
| MA (1) | MA27019A1 (fr) |
| MX (1) | MXPA03009124A (fr) |
| NO (1) | NO20034470L (fr) |
| NZ (1) | NZ529304A (fr) |
| PL (1) | PL365220A1 (fr) |
| PT (1) | PT1384477E (fr) |
| RU (1) | RU2305545C2 (fr) |
| UA (1) | UA75402C2 (fr) |
| WO (1) | WO2002080909A1 (fr) |
| ZA (1) | ZA200308626B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2238923B1 (es) * | 2004-02-16 | 2006-11-01 | Laboratorios Del Dr. Esteve, S.A. | Nuevos derivados pirazolinicos sustituidos. |
| KR20070044799A (ko) * | 2004-02-16 | 2007-04-30 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 암 치료에 유용한 피라졸린 유도체 |
| TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| US7998996B2 (en) | 2004-02-17 | 2011-08-16 | Laboratorios Del Dr. Esteve S.A. | Substituted pyrazoline compounds for reducing triglycerides in blood |
| EP1637522A1 (fr) * | 2004-09-16 | 2006-03-22 | Laboratorios Del Dr. Esteve, S.A. | Composés de pyrazolines substituées pour réduire des triglycerides dans le sang |
| BRPI0507790A (pt) * | 2004-02-17 | 2007-07-17 | Esteve Labor Dr | composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos |
| ES2327379B1 (es) * | 2005-07-15 | 2010-05-28 | Laboratorios Del Dr. Esteve, S.A. | Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos. |
| WO2007009707A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de composes a base de pyrazoline substitues pour le traitement de maladies liees a la coagulation |
| EP1749527A1 (fr) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Utilisation des derivés du pyrazole pour le traitement du syndrome métabolique |
| EP1849784A1 (fr) * | 2006-04-26 | 2007-10-31 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de la pyrazoline Indoline-substituée, leur préparation and utilisation comme médicaments |
| EP1743892A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Composés pyrazoline substitués, leur préparation et utilisation comme médicaments |
| ES2334967B1 (es) * | 2005-07-15 | 2010-10-21 | Laboratorios Del Dr. Esteve, S.A. | Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre. |
| WO2007009699A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Utilisation de composes pyrazoliniques substitues et de leurs derives contre des affections associees au systeme des cannabinoides |
| WO2007009702A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Composes de pyrazoline substitues, leur preparation et leur utilisation comme medicaments |
| EP1743889A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang |
| EP1743890A1 (fr) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Dérivés 4,5-dihydro-1H-pyrazole, leur, préparation et utilisation comme médicaments. |
| EP1749525A1 (fr) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Combination de pyrazoline substitués et de médicaments contre la dépendance |
| WO2007009701A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de composes pyrazoliniques substitues pour traiter des facteurs de risque cardiovasculaires imputables a des troubles du metabolisme ou de l'alimentation |
| WO2007009693A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr.Esteve, S.A | Combinaison d'un compose pyrazolinique substitue et medicament utilise pour des troubles en lien avec les aliments |
| EP1849776A1 (fr) * | 2006-04-26 | 2007-10-31 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de la pyrazoline azépane- ou azocane-substituées, leur préparation et utilisation comme médicaments |
| EP1746090A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios del Dr. Esteve S.A. | Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang |
| WO2007009700A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique |
| EP1743637A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Utilisation des derivés du pyrazole seuls ou en combinaison pour le traitement du syndrome métabolique |
| EP1743643A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Nouvelles formulations de composés à base de pyrazoline |
| ES2326724B1 (es) * | 2005-07-15 | 2010-05-11 | Laboratorios Del Dr. Esteve, S.A. | Nuevas formulaciones de compuestos de pirazolina sustituidos. |
| US7897589B2 (en) | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| ES2326725B1 (es) * | 2005-07-15 | 2010-05-11 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada. |
| EP1749526A1 (fr) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Utilisation des derivés de la pyrazoline pour le traitement des troubles alimentaires, comme l'obesité ou le syndrome métabolique chez les patients diabetiques |
| EP1743636A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Combinaison d'une pyrazoline substituée avec un agent utilisé contre les dérangements alimentaires |
| EP1743639A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Utilisation des derivés de la pyrazoline pour le traitement des troubles liées à la coagulation |
| WO2007009691A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Combinaison de substances active s |
| EP1743642A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de composés à base de pyrazoline pour le traitement des maladies associées avec le système cannabinoïde |
| KR101457637B1 (ko) * | 2012-10-24 | 2014-11-20 | 건국대학교 산학협력단 | 디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물 |
| CN103664785A (zh) * | 2013-11-04 | 2014-03-26 | 南京大学 | 一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
| US20230082841A1 (en) * | 2021-09-14 | 2023-03-16 | Maverick Gold (NV) LLC | Methods and systems for titling and trading alternative reserves |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0674624T3 (da) * | 1992-12-17 | 1999-09-13 | Pfizer | Pyrazoler med CRF-antagonistisk aktivitet |
| CA2277954A1 (fr) * | 1993-11-30 | 1995-06-08 | G.D. Searle & Co. | Benzenesulfonamides de pyrazolyle substitues destines au traitement des inflammations |
| US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| ES2137138B1 (es) * | 1998-05-29 | 2000-09-16 | Esteve Labor Dr | Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos. |
| KR100796851B1 (ko) * | 1999-06-16 | 2008-01-22 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 사이클록시게나아제-2의 억제제로서 1-(4-설파밀아릴)-3-치환형-5-아릴-2-피라졸린 |
-
2001
- 2001-04-06 ES ES200100818A patent/ES2174757B1/es not_active Expired - Fee Related
-
2002
- 2002-03-21 DE DE60211681T patent/DE60211681T2/de not_active Expired - Lifetime
- 2002-03-21 BR BR0208805-3A patent/BR0208805A/pt not_active IP Right Cessation
- 2002-03-21 PT PT02714233T patent/PT1384477E/pt unknown
- 2002-03-21 ES ES02714233T patent/ES2264723T3/es not_active Expired - Lifetime
- 2002-03-21 PL PL02365220A patent/PL365220A1/xx not_active Application Discontinuation
- 2002-03-21 CA CA2442974A patent/CA2442974C/fr not_active Expired - Fee Related
- 2002-03-21 CN CNB028098935A patent/CN1299682C/zh not_active Expired - Fee Related
- 2002-03-21 MX MXPA03009124A patent/MXPA03009124A/es active IP Right Grant
- 2002-03-21 JP JP2002578948A patent/JP4451599B2/ja not_active Expired - Fee Related
- 2002-03-21 HU HU0400918A patent/HUP0400918A3/hu unknown
- 2002-03-21 WO PCT/ES2002/000137 patent/WO2002080909A1/fr not_active Ceased
- 2002-03-21 ZA ZA200308626A patent/ZA200308626B/en unknown
- 2002-03-21 AT AT02714233T patent/ATE326966T1/de not_active IP Right Cessation
- 2002-03-21 RU RU2003132457/15A patent/RU2305545C2/ru not_active IP Right Cessation
- 2002-03-21 EP EP04030751A patent/EP1516621A3/fr not_active Withdrawn
- 2002-03-21 UA UA2003119998A patent/UA75402C2/uk unknown
- 2002-03-21 DK DK02714233T patent/DK1384477T3/da active
- 2002-03-21 IL IL15826902A patent/IL158269A0/xx unknown
- 2002-03-21 CN CNA2005100713090A patent/CN1698602A/zh active Pending
- 2002-03-21 NZ NZ529304A patent/NZ529304A/en unknown
- 2002-03-21 US US10/312,193 patent/US20040034082A1/en not_active Abandoned
- 2002-03-21 AU AU2002246152A patent/AU2002246152B2/en not_active Ceased
- 2002-03-21 EP EP02714233A patent/EP1384477B1/fr not_active Expired - Lifetime
- 2002-03-21 KR KR10-2003-7013062A patent/KR20040025912A/ko not_active Ceased
-
2003
- 2003-10-03 IS IS6973A patent/IS6973A/is unknown
- 2003-10-06 NO NO20034470A patent/NO20034470L/no not_active Application Discontinuation
- 2003-11-05 MA MA27382A patent/MA27019A1/fr unknown
-
2006
- 2006-08-03 CY CY20061101088T patent/CY1105523T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1384477T3 (da) | Anvendelse af pyrazolinderivater ved fremstilling af et medikament til forebyggelse og/eller behandling af proliferative cellesygdomme | |
| RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
| ES8400729A1 (es) | Procedimiento para la preparacion de nuevos derivados de la aminometil-5-aril-3-oxazolidinona-2. | |
| NZ508990A (en) | Pyrazoline derivatives, their preparation and application as medicaments | |
| HUP0002495A1 (hu) | VLA-4 Által közvetített leukocita adhéziót gátló dipeptidszármazékok és rokon vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MA27908A1 (fr) | Agents therapeutiques utiles pour le traitement de la douleur | |
| GB9202791D0 (en) | Compounds | |
| MA27390A1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| FI961914A0 (fi) | Lyhytvaikutteiset dihydropyridiinit | |
| NO20005179L (no) | Medikament behandling | |
| MD382C2 (ro) | Procedeu de obţinere a piperazinilalchil-3(2H)-piridazinonelor sau a sărurilor lor farmaceutice admisibile | |
| MA29961B1 (fr) | Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique | |
| ZA912886B (en) | Cyclic hydroxamic acids and their use | |
| DE69103630D1 (de) | Oxazolederivate, ihre herstellung und diese enthaltende pharmazeutischen zubereitungen. | |
| DZ1726A1 (fr) | Médicament contenant des composés imidazol-1-yliques. | |
| DE69413831D1 (de) | Phenoxyphenylcyclopentenyl-hydroxyharnstoffe | |
| MA27712A1 (fr) | Triazoles utiles en therapeutique | |
| DE60104589D1 (de) | Therapeutisches Mittel zur Behandlung von Dermatitis | |
| DK0772630T3 (da) | Streptograminderivater, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser | |
| ATE250027T1 (de) | Azetidincarboxamidderivate zur behandlung von zns-erkrankungen | |
| FR2869316A1 (fr) | Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique. | |
| DE69418347D1 (de) | Benzoxazinderivate, verfahren diese zu erhalten und ihre verwendung als medikamente | |
| HUP9801985A2 (hu) | Cisztinszármazékok alkalmazása restenózis gyógyítására használható gyógyszerkészítmények előállítására | |
| FR2870725A1 (fr) | Composition pour le traitement de fibres keratiniques comprenant un compose polycarboxylique particulier et un coupleur particulier, procede et dispositif la mettant en oeuvre | |
| EP0240721A3 (fr) | Agent thérapeutique de traitement des maladies circulatoires périphériques |